SCHEMBL903617

SCHEMBL903617

CCOC(=O)[C@@H]1CCC(=O)N1C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 2/20 0.39
MAPT P10636 1/20 0.39
GLA P06280 2/20 0.38
FKBP1A P62942 2/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
WNT3 P56703 1/20 0.36
SFRP1 Q8N474 1/20 0.36
ADRA1A P35348 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
ACE P12821 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL946514 1.00 MEN1 (0.39) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL862733 1.00 MEN1 (0.39) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL16584576 0.92 FKBP1A (0.41) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL15281912 0.92 FKBP1A (0.41) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL8266791 0.92 FKBP1A (0.41) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL3366889 0.87 KLK7 (0.34) MEN1KMT2AALDH1A1FKBP1ACHRM2
SCHEMBL16082361 0.87 KLK7 (0.34) MEN1KMT2AALDH1A1FKBP1ACHRM2
SCHEMBL1372911 0.87 CHRM2 (0.41) MAPTCHRM2CHRM1CHRM3WNT3
SCHEMBL713924 0.87 CHRM2 (0.41) MAPTCHRM2CHRM1CHRM3WNT3
SCHEMBL30289778 0.87 CHRM2 (0.41) MAPTCHRM2CHRM1CHRM3WNT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116466003-A Separation method of N-Boc-L-pyroglutamic acid ethyl ester enantiomer and application thereof 广西奕安泰药业有限公司 2023-07-21 CN claimed
WO-2023002984-A1 METHOD FOR PRODUCING IMIDAZOLE COMPOUND 小野薬品工業株式会社 2023-01-26 WO claimed
CN-217534000-U BOC-L-pyroglutamic acid ethyl ester feeding storage device 南京安淮创新药物研究院有限公司 2022-10-04 CN claimed
CN-110498762-B Synthesis method of (2S,5R) -5- [ (benzyloxy) amino ] -piperidine-2-ethyl formate 山东安信制药有限公司 2020-10-27 CN claimed
CN-104628622-A Preparation method of saxagliptin intermediate SHANGHAI INST TECHNOLOGY 2015-05-20 CN claimed
US-8809024-B2 Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor ASTRAZENECA AB (SE) 2014-08-19 US claimed
US-20130204012-A1 Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor BRISTOL-MYERS SQUIBB COMPANY (US) 2013-08-08 US claimed
WO-2013111158-A2 PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR MSN LABORATORIES LIMITED (IN) 2013-08-01 WO claimed
CN-122010942-A Chemical synthesis method of avibactam sodium 山东安信制药有限公司 2026-05-12 CN disclosed
EP-3854786-B1 METHOD FOR PRODUCING AMINO ACID DERIVATIVES UBE CORP (JP) 2026-02-18 EP disclosed
EP-4640684-A1 KRAS G12D INHIBITORS AND USES THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-10-29 EP disclosed
CN-120794902-A Synthesis method of (2S, 5R) -5- [ (phenylmethoxy) amino ] -2-piperidinecarboxylic acid ethyl ester oxalate 青岛华商新耀医药科技有限公司 2025-10-17 CN disclosed
EP-4551577-A1 FUSED RING KRAS INHIBITORS FOR TREATING DISEASE Blossomhill Therapeutics, Inc. (US) 2025-05-14 EP disclosed
US-12286429-B2 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-04-29 US disclosed
US-20040259843-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) ABBVIE INC. 2004-12-23 US disclosed
WO-2004052850-A2 METHODS AND COMPOUNDS PRODUCING DIPEPTIDYL PEPTIDASE IV INHIBITORS AND INTERMEDIATES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2004-06-24 WO disclosed
US-20040106826-A1 Process for synthesizing L--methylene glutamic acid and analogs BIONUMERIK PHARMACEUTICALS, INC. 2004-06-03 US disclosed
WO-2004039314-A2 PROCESS FOR SYNTHESIZING L-Y-METHYLENE GLUTAMIC ACID AND ANALOGS BIONUMERIK PHARMACEUTICALS, INC. (US) 2004-05-13 WO disclosed
US-6395767-B2 ANTIDIABETIC AGENTS; SAXAGLIPTIN BRISTOL-MYERS SQUIBB COMPANY 2002-05-28 US disclosed
US-20020019411-A1 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method ASTRAZENECA AB (SE) 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12286429-B2 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors F11, F12, F13A1 MEN1 1926/4885KMT2A 983/4885ALDH1A1 2307/4885
US-20040106826-A1 Process for synthesizing L--methylene glutamic acid and analogs GLUL, QPCT, RIMKLA MEN1 661/4885KMT2A 480/4885ALDH1A1 2405/4885
US-20020019411-A1 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method DPP4, DPP3, DPP7 MEN1 4082/4885KMT2A 4285/4885ALDH1A1 1033/4885
US-20040259843-A1 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) DPP4, DPP3, DPP7 MEN1 3576/4885KMT2A 3404/4885ALDH1A1 2295/4885
US-20130204012-A1 Process For Preparing Dipeptidyl Peptidase IV Inhibitors And Intermediates Therefor DNPEP, DPP4, PEPD MEN1 2318/4885KMT2A 2694/4885ALDH1A1 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.